

[Clin Cancer Res.](#) 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164. Online ahead of print.

Glioma Response to IDH Inhibition: Real-World Experience

Rimas V Lukas ¹, Craig Horbinski ²

Affiliations

PMID: 37738033 DOI: [10.1158/1078-0432.CCR-23-2164](https://doi.org/10.1158/1078-0432.CCR-23-2164)

Abstract

Treatment of IDH mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. IDH inhibition has a therapeutic benefit in patients with these tumors.